Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427836 | 0.93 | DHFR (0.42) | DHFRHRH4APPSMN1; SMN2 | |
| SCHEMBL14520705 | 0.89 | HRH4 (0.52) | DHFRHRH4APPCRHR1 | |
| SCHEMBL14520706 | 0.81 | DHFR (0.41) | DHFRHRH4SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL14520710 | 0.81 | DHFR (0.55) | DHFR | |
| SCHEMBL14520713 | 0.81 | DHFR (0.57) | DHFR | |
| SCHEMBL14520703 | 0.81 | MEN1 (0.49) | DHFRHRH4APPSMN1; SMN2ADORA3 | |
| SCHEMBL14520708 | 0.80 | IDO1 (0.41) | DHFRHRH4ADORA3ADORA2AADORA1 | |
| SCHEMBL14520707 | 0.77 | DHFR (0.48) | DHFRADORA3ADORA2AADORA1 | |
| SCHEMBL14520709 | 0.76 | CD38 (0.44) | DHFRADORA3ADORA2AADORA1 | |
| SCHEMBL14520712 | 0.73 | KCNH2 (0.47) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | disclosed |
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | LIG3, LIG1, NQO1 | DHFR 171/4885HRH4 1168/4885APP 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.